Liver health study for mild liver disease
Part of Digestive system clinical trials.
This study tests an experimental medicine called ABI-6250 in people with mild liver problems compared to healthy people. It aims to see how the drug affects the body and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mild liver disease (Child-Pugh Class A)
- You are between 18 and 45 Body Mass Index (BMI), which is a measure of body fat based on height and weight
- You are not a smoker or smoke very little
- You can swallow whole tablets without chewing
- You are willing to stay at the research clinic for the study and return for follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This study tests a new medicine for people with mild or moderate liver problems to see how the liver affects the drug in the body. It also includes people with normal liver function for comparison.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This trial tests a new medicine called ABI-6250 for people with chronic hepatitis D. It aims to see if the drug is safe and helps control the infection.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
Hear when a new Mild Hepatic Imparement trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.